Biotech Is Headed Toward A Cliff In 2009, Finance Experts Predict
This article was originally published in The Pink Sheet Daily
Executive Summary
Economic crisis’ impact on industry rationalization and financing are key topics during the Wharton Health Care Business conference.
You may also be interested in...
Troubled Biotechs: Intercytex, Vanda, Advanced Life Sciences
With disappointing data from its lead program, the UK’s InterCytex is considering all options, including merger. In the U.S., Vanda is facing shareholder activism while Advanced Life Sciences is in the odd position of not being able to afford good news from FDA.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.